Tuesday, August 18, 2026
ExploreSearch
Finance Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· November 10, 2025

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

View original at globenewswire.com
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Azenosertib is a potentially first-in-class and best-in-class WEE1 inhibitor

    80% confidence

  • Company expects to disclose topline data from DENALI Part 2 by year end 2026

    80% confidence

  • Further development in USC will be limited to partnering or the Company's ability to allocate capital to this indication

    80% confidence

  • Results from the TETON trial are planned for publication in the first half of 2026

    80% confidence

  • DENALI Part 2, if successful, has the potential to support an accelerated approval, subject to FDA review

    80% confidence

  • DENALI clinical trial remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback

    80% confidence

  • In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types

    80% confidence

  • $280.7 million in cash provides runway into late 2027

    80% confidence

  • Existing cash, cash equivalents and marketable securities as of September 30, 2025 will be sufficient to fund operating expenses requirements into late 2027

    80% confidence

Cited in these Via News reports